The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| SomaKit TOC edotreotide Orphan | Novartis Europharm Limited | Neuroendocrine Tumors; Radionuclide Imaging | 🇪🇺 EU 2016-12-08 | Order → |
| Tenofovir disoproxil Viatris (previously Tenofovir disoproxil Mylan) tenofovir disoproxil Generic | Viatris Limited | HIV Infections | 🇪🇺 EU 2016-12-08 | Order → |
| Venclyxto venetoclax | AbbVie Deutschland GmbH & Co. KG | Leukemia, Lymphocytic, Chronic, B-Cell | 🇪🇺 EU 2016-12-04 | Order → |
| Ninlaro ixazomib Orphan | Takeda Pharma A/S | Multiple Myeloma | 🇪🇺 EU 2016-11-21 | Order → |
| Granpidam sildenafil Generic | Accord Healthcare S.L.U. | Hypertension, Pulmonary | 🇪🇺 EU 2016-11-14 | Order → |
| Glyxambi empagliflozin;linagliptin | Boehringer Ingelheim International GmbH | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2016-11-11 | Order → |
| Ivabradine JensonR ivabradine Generic | JensonR+ Limited | Angina Pectoris; Heart Failure | 🇪🇺 EU 2016-11-11 | Order → |
| Ivabradine Zentiva ivabradine Generic | Zentiva k.s. | Angina Pectoris; Heart Failure | 🇪🇺 EU 2016-11-11 | Order → |
| Parsabiv etelcalcetide | Amgen Europe B.V. | Hyperparathyroidism, Secondary | 🇪🇺 EU 2016-11-11 | Order → |
| Emtricitabine/Tenofovir disoproxil Zentiva emtricitabine;tenofovir disoproxil Generic | Zentiva k.s. | HIV Infections | 🇪🇺 EU 2016-11-09 | Order → |
| Ibrance palbociclib | Pfizer Europe MA EEIG | Breast Neoplasms | 🇪🇺 EU 2016-11-09 | Order → |
| Lartruvo olaratumab ConditionalAccelerated assessmentAdditional monitoring | Eli Lilly Nederland B.V. | Sarcoma | 🇪🇺 EU 2016-11-09 | Order → |
| Onivyde pegylated liposomal (previously Onivyde) irinotecan hydrochloride trihydrate Orphan | Les Laboratoires Servier | Pancreatic Neoplasms | 🇪🇺 EU 2016-10-14 | Order → |
| Truberzi eluxadoline Additional monitoring | Allergan Pharmaceuticals International Limited | Irritable Bowel Syndrome; Diarrhea | 🇪🇺 EU 2016-09-19 | Order → |
| Inhixa enoxaparin sodium Biosimilar | Techdow Pharma Netherlands B.V. | Venous Thromboembolism | 🇪🇺 EU 2016-09-15 | Order → |
| Mysildecard sildenafil Generic | Viatris Limited | Hypertension, Pulmonary | 🇪🇺 EU 2016-09-15 | Order → |
| Sialanar glycopyrronium bromide | Proveca Pharma Limited | Sialorrhea | 🇪🇺 EU 2016-09-15 | Order → |
| Tenofovir disoproxil Zentiva tenofovir disoproxil Generic | Zentiva k.s. | HIV Infections | 🇪🇺 EU 2016-09-15 | Order → |
| Thorinane enoxaparin sodium BiosimilarAdditional monitoring | Pharmathen S.A. | Venous Thromboembolism | 🇪🇺 EU 2016-09-14 | Order → |
| Cabometyx cabozantinib Accelerated assessment | Ipsen Pharma | Carcinoma, Renal Cell; Carcinomas, Hepatocellular | 🇪🇺 EU 2016-09-09 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.